A Drug Pill Which Could Change How Medicines Will Be Priced Forever

Assume your doctor prescribes a drug to you. The brand-name version costs $300 a month. Another generic drug on the other hand will cost $30. As most people would, you would also purchase the cheaper one. That generic cheaper bottle exists as a result of a delicate legal balancing act, an act that the U.S. Supreme Court is now reconsidering in a case that could change pharmaceutical competition for decades.

The center of the case Hikma Pharmaceuticals v. Amarin is “skinny label”. Amarin, a brand-name manufacturer approved its drug for multiple uses but, only some of them are under patent. Therefore, a generic manufacturer can legally enter the market by simply carving out the patented uses from their label, thus producing a label that is skinner than the original brand-name’s label.

Understanding How Generic Drugs Enter the Market

The Hatch-Waxman Act of 1984 created a legal entry for generic manufactures without having to run the same lengthy clinical trials as brand-name drugs. They can piggyback on the original drug’s safety data after the relevant patent expires.

But a pharmaceutical company rarely patents their drug just once. Once the drug is approved for one use, after extensive research it may be discovered that the same drug also works for something else. They then patent that new use separately. Now, the drug has one use that is off-patent and open to generics, and another use that is heavily protected.

This is where skinny label comes in. The law allows generic manufacturers to get approval for the unpatented uses of the said drug, removing the patented uses from their label entirely. The label thus becomes “skinny” as it only describes fewer uses than the original. The FDA intentionally created this to help generics enter the market sooner helping keep the drug prices lower for patients.

This worked well for years until, Vascepa.

A $300 Million Question and a Fish-Oil Drug

 Amarin Pharma makes a purified fish-oil capsule which is approved for two purposes — Vascepa. The first: treating high triglycerides. The second: reducing the risk of cardiovascular events in high-risk patients. The second use was discovered after a massive clinical trial costing approximately $300 million.

Hikma, a generic pharmaceutical company, wanted to sell a cheaper version of Vascepa. They applied for FDA approval only for the unpatented triglyceride indication and entirely left out the cardiovascular use from their label. The FDA subsequently approved their application, Hikma then launched their generic version.

Amarin sued Hikma arguing that the label itself wasn’t the problem, but what Hikma did around the label. Hikma’s press release described their drug as a “generic version of Vascepa” without clarifying that it was only approved for lesser uses. Vascepa’s total sales figures were citied, including revenue from the patented cardiovascular use and their website described it in a therapeutic category which was broader than what their skinny label covered. Amarin argued that Himka was implicitly inviting doctors to prescribe the generic version for heart disease by marketing their drug as a straight “generic version of Vascepa”.

Why The Courts Disagreed

 Delaware’s District Court dismissed Amarin’s case because the judges found Hikma’s statements weren’t specific enough to include the patented use. They called the “generic version” too vague to count as actively inducing infringement.

In 2024, the Federal Circuit Court of appeals reversed this decision. They held that Hikma’s label cannot be evaluated in isolation. When the skinny label, press release, sales figures and the website language is combined, the complaint was at least plausible to proceed to trial. The court didn’t hold Hikma guilty, but that the case deserved to be heard. Hikma appealed to the Supreme Court in January 2026.

Hikma posed the Supreme Court with two legal questions.

The first: by calling its product a “generic version” and referencing the brand drug’s public sales data can the company be accused of inducing infringement even though the label fully carves out a patented use?

The second: if the company never encouraged, or even mentioned the patented use, can the company be liable for inducing infringement of the patented use?

The answer to these questions will define and pave the path for every other generic drug launch in America. Generic manufacturers will need lawyers scrutinizing every press release, every word on their website, if merely calling a drug the “generic version” triggers an infringement lawsuit.

What’s at Stake

If the Court decides in Amarin’s favor, generic manufacturers will have to scrutinize every press release and anything else that could be used against them in the court even though they have carved out the patented use from their label. This creates a chain where for the generic manufacturers legal teams get bigger and expensive, launches are delayed and at the end of this chain a patient ends up paying full price for the drug that was supposed to be cheaper.

On the other hand, Amarin spent approximately $300 million proving that Vascepa could reduce heart related risks. Amarin argued that such exuberant spending is only justified when patent protection is granted on such new uses. Why would any brand name invest in such trials if any generic manufacturer can receive the benefits of the trials without having to fund it?

These questions make the stakes asymmetric and further difficult to decide on. A win for Amarin comes with the risk of making generic versions more expensive and a win for Hikma comes with the risk of brand names not investing in breakthrough trials.

As on April 29, 2026 the Justices are reserved on making changes to the inducement law. Many questioned as to why the matter was being tried as the dispute can be resolved without a new doctrine.

The justices are expected to finally decide the case by July and the Court’s decision may be narrower than expected. The court may just lay down clarifications regarding what a complaint must actually allege to actually dismiss a skinny label rather than changing induced infringement laws for the entire pharmaceutical industry.

Next time a patient stands in a pharmacy choosing between a brand-name drug and a cheaper generic version, the decision will already be made by the Court’s ruling.

On the surface, Hikma v. Amarin is a dispute regarding a fish-oil drug and press releases. Under all this, lies American Healthcare’s core principle, affordable medicine. The Supreme Court’s decision will reshape how the law will accommodate both, the protection rights of the brand-name manufacturers and ensuring generic version still remain affordable.

Reference:

1. https://www.duanemorris.com/alerts/us_supreme_court_grants_certiorari_hikma_ama html
2. https://www.mofo.com/resources/insights/260120-supreme-court-takes-up-hikma-v-amarin
3. https://www.finnegan.com/en/insights/articles/skinny-labels-larger-risks-supreme-court-considers-induced-infringement-standards-in-hikma-v-amarin.html
4. https://www.crowell.com/en/insights/client-alerts/are-skinny-labels-getting-heavier-for-generics-key-takeaways-from-hikma-v-amarin-the-supreme-courts-first-patent-case-since-2023
5. https://www.usnews.com/news/national-news/articles/2026-04-29/hikma-v-amarin-supreme-court-weighs-future-of-skinny-labeling
6. https://ipwatchdog.com/2026/04/29/justices-voice-concern-upholding-cafcs-hikma-ruling-will-harm-generics-industry/

7. https://www.biosimilarsip.com/2026/01/20/supreme-court-to-address-skinny-label-patent-disputes/
8. https://patentdocs.org/2026/05/04/hikma-v-amarin-the-amici-speak-part-i/
9. https://www.aipla.org/detail/news/2026/03/31/aipla-files-amicus-brief-in-hikma-pharmaceuticals-usa-inc.-v.-amarin-pharma--inc

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.